Restoration of cyclin D2 has an inhibitory potential on the proliferation of LNCaP cells

Biochemical and Biophysical Research Communications

Volumn 387, Issue 1, 2009, Pages 196-201

  Kobayashi, Takashi ^a,b   Nakamura, Eijiro ^a   Shimizu, Yosuke ^a   Terada, Naoki ^a   Maeno, Atsushi ^a   Kobori, Go ^a   Kamba, Tomomi ^a   Kamoto, Toshiyuki ^a   Ogawa, Osamu ^a   Inoue, Takahiro ^a  

^a KYOTO UNIVERSITY   (Japan)

^b NONE

Author keywords

Androgen receptor; Carcinogenesis; Cell death; D type cyclin; Prevention; Proliferation; Prostatic adenocarcinoma

Indexed keywords

ANDROGEN RECEPTOR; CYCLIN D1; CYCLIN D2; DNA; RETROVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER PREVENTION; CARCINOGENESIS; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DELETION MUTANT; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; MOUSE; NONHUMAN; NUDE MOUSE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLINS; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MUTATION; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANDROGEN;

EID: 67651036152     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.06.146     Document Type: Article

References (24)

1. J. Ferlay, F. Bray, P. Pisani, D. Parkin, Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0, ed., IARC Press, Lyon, 2001.
2. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., and Thun M.J. Cancer statistics, 2006. CA Cancer J. Clin. 56 (2006) 106-130
3. Nelson W.G., De Marzo A.M., and Isaacs W.B. Prostate cancer. N. Engl. J. Med. 349 (2003) 366-381
4. Patra S.K., Patra A., and Dahiya R. Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem. Biophys. Res. Commun. 287 (2001) 705-713
5. Lin X., Tascilar M., Lee W.H., Vles W.J., Lee B.H., Veeraswamy R., Asgari K., Freije D., van Rees B., Gage W.R., Bova G.S., Isaacs W.B., Brooks J.D., DeWeese T.L., De Marzo A.M., and Nelson W.G. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am. J. Pathol. 159 (2001) 1815-1826
6. Whang Y.E., Wu X., Suzuki H., Reiter R.E., Tran C., Vessella R.L., Said J.W., Isaacs W.B., and Sawyers C.L. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl. Acad. Sci. USA 95 (1998) 5246-5250
7. Lu S., Tsai S.Y., and Tsai M.J. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res. 57 (1997) 4511-4516
8. Graff J.R., Herman J.G., Lapidus R.G., Chopra H., Xu R., Jarrard D.F., Isaacs W.B., Pitha P.M., Davidson N.E., and Baylin S.B. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 55 (1995) 5195-5199
9. Padar A., Sathyanarayana U.G., Suzuki M., Maruyama R., Hsieh J.T., Frenkel E.P., Minna J.D., and Gazdar A.F. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin. Cancer Res. 9 (2003) 4730-4734
10. Henrique R., Costa V.L., Cerveira N., Carvalho A.L., Hoque M.O., Ribeiro F.R., Oliveira J., Teixeira M.R., Sidransky D., and Jeronimo C. Hypermethylation of cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J. Mol. Med. 84 (2006) 911-918
11. Yu Y.P., Landsittel D., Jing L., Nelson J., Ren B., Liu L., McDonald C., Thomas R., Dhir R., Finkelstein S., Michalopoulos G., Becich M., and Luo J.H. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 22 (2004) 2790-2799
12. Tashiro E., Tsuchiya A., and Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci. 98 (2007) 629-635
13. Hanson J.A., Gillespie J.W., Grover A., Tangrea M.A., Chuaqui R.F., Emmert-Buck M.R., Tangrea J.A., Libutti S.K., Linehan W.M., and Woodson K.G. Gene promoter methylation in prostate tumor-associated stromal cells. J. Natl. Cancer Inst. 98 (2006) 255-261
14. Henrique R., Jeronimo C., Teixeira M.R., Hoque M.O., Carvalho A.L., Pais I., Ribeiro F.R., Oliveira J., Lopes C., and Sidransky D. Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol. Cancer Res. 4 (2006) 1-8
15. Inoue T., Yoshida T., Shimizu Y., Kobayashi T., Yamasaki T., Toda Y., Segawa T., Kamoto T., Nakamura E., and Ogawa O. Requirement of androgen-dependent activation of protein kinase Czeta for androgen-dependent cell proliferation in LNCaP Cells and its roles in transition to androgen-independent cells. Mol. Endocrinol. 20 (2006) 3053-3069
16. Lee S., Nakamura E., Yang H., Wei W., Linggi M.S., Sajan M.P., Farese R.V., Freeman R.S., Carter B.D., Kaelin Jr. W.G., and Schlisio S. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8 (2005) 155-167
17. Inoue T., Nakanishi H., Inada K., Hioki T., Tatematsu M., and Sugimura Y. Real time reverse transcriptase polymerase chain reaction of urinary cytokeratin 20 detects transitional cell carcinoma cells. J. Urol. 166 (2001) 2134-2141
18. Baker G.L., Landis M.W., and Hinds P.W. Multiple functions of D-type cyclins can antagonize pRb-mediated suppression of proliferation. Cell Cycle 4 (2005) 330-338
19. Iguchi K., Ishii K., Nakano T., Otsuka T., Usui S., Sugimura Y., and Hirano K. Isolation and characterization of LNCaP sublines differing in hormone sensitivity. J. Androl. 28 (2007) 670-678
20. Knudsen K.E., Cavenee W.K., and Arden K.C. D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res. 59 (1999) 2297-2301
21. Petre-Draviam C.E., Williams E.B., Burd C.J., Gladden A., Moghadam H., Meller J., Diehl J.A., and Knudsen K.E. A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene 24 (2005) 431-444
22. Davis J.N., Wojno K.J., Daignault S., Hofer M.D., Kuefer R., Rubin M.A., and Day M.L. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res. 66 (2006) 11897-11906
23. Lim J.T., Mansukhani M., and Weinstein I.B. Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. Proc. Natl. Acad. Sci. USA 102 (2005) 5156-5161
24. Blagosklonny M.V. Cell senescence and hypermitogenic arrest. EMBO Rep. 4 (2003) 358-362